CASI Pharmaceuticals Inc. [NASDAQ: CASI] slipped around -0.2 points on Monday, while shares priced at $1.35 at the close of the session, down -12.90%. The company report on August 12, 2021 that CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results.
– EVOMELA Second Quarter 2021 Revenue Continues Upward Trend; Revenue Growth Guidance in 2021 Revised to Exceed 80% Over 2020 -.
– CID-103 Reaches Milestone with Dosing of First Patient -.
CASI Pharmaceuticals Inc. stock is now -54.24% down from its year-to-date (YTD) trading value. CASI Stock saw the intraday high of $1.54 and lowest of $1.34 per share. The company’s 52-week high price is 3.90, which means current price is +18.94% above from all time high which was touched on 01/26/21.
Compared to the average trading volume of 1.38M shares, CASI reached a trading volume of 7973679 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CASI Pharmaceuticals Inc. [CASI]?
BTIG Research have made an estimate for CASI Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2021. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on April 26, 2021, representing the official price target for CASI Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $5, while Oppenheimer analysts kept a Outperform rating on CASI stock.
The Average True Range (ATR) for CASI Pharmaceuticals Inc. is set at 0.11, with the Price to Sales ratio for CASI stock in the period of the last 12 months amounting to 8.75. The Price to Book ratio for the last quarter was 1.99, with the Price to Cash per share for the same quarter was set at 0.51.
How has CASI stock performed recently?
CASI Pharmaceuticals Inc. [CASI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.67. With this latest performance, CASI shares gained by 16.38% in over the last four-week period, additionally sinking by -43.98% over the last 6 months – not to mention a drop of -16.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CASI stock in for the last two-week period is set at 42.13, with the RSI for the last a single of trading hit 34.73, and the three-weeks RSI is set at 45.11 for CASI Pharmaceuticals Inc. [CASI]. The present Moving Average for the last 50 days of trading for this stock 1.3652, while it was recorded at 1.5520 for the last single week of trading, and 2.0642 for the last 200 days.
CASI Pharmaceuticals Inc. [CASI]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and CASI Pharmaceuticals Inc. [CASI] shares currently have an operating margin of -223.01 and a Gross Margin at +27.30. CASI Pharmaceuticals Inc.’s Net Margin is presently recorded at -321.89.
Return on Total Capital for CASI is now -33.02, given the latest momentum, and Return on Invested Capital for the company is -61.70. Return on Equity for this stock declined to -62.49, with Return on Assets sitting at -41.92. When it comes to the capital structure of this company, CASI Pharmaceuticals Inc. [CASI] has a Total Debt to Total Equity ratio set at 3.92. Additionally, CASI Total Debt to Total Capital is recorded at 3.77, with Total Debt to Total Assets ending up at 2.50. Long-Term Debt to Equity for the company is recorded at 1.18, with the Long-Term Debt to Total Capital now at 1.14.
Reflecting on the efficiency of the workforce at the company, CASI Pharmaceuticals Inc. [CASI] managed to generate an average of -$335,326 per employee. Receivables Turnover for the company is 5.05 with a Total Asset Turnover recorded at a value of 0.13.CASI Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.00 and a Current Ratio set at 8.30.
Insider trade positions for CASI Pharmaceuticals Inc. [CASI]
There are presently around $63 million, or 33.50% of CASI stock, in the hands of institutional investors. The top three institutional holders of CASI stocks are: CONSONANCE CAPITAL MANAGEMENT LP with ownership of 10,321,956, which is approximately -2.075% of the company’s market cap and around 3.70% of the total institutional ownership; FEDERATED HERMES, INC., holding 10,150,000 shares of the stock with an approximate value of $13.7 million in CASI stocks shares; and IDG-ACCEL CHINA GROWTH FUND III ASSOCIATES L.P., currently with $10.76 million in CASI stock with ownership of nearly 0% of the company’s market capitalization.
Positions in CASI Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 33 institutional holders increased their position in CASI Pharmaceuticals Inc. [NASDAQ:CASI] by around 3,871,534 shares. Additionally, 56 investors decreased positions by around 10,158,241 shares, while 14 investors held positions by with 32,709,115 shares. The mentioned changes placed institutional holdings at 46,738,890 shares, according to the latest SEC report filing. CASI stock had 18 new institutional investments in for a total of 1,208,270 shares, while 33 institutional investors sold positions of 4,153,267 shares during the same period.